The cholesterol-lowering drug fenofibrate cuts cardiovascular disease risks by 30 per cent in women with type-2 diabetes, according to a study done at th University of Sydney in Australia and published in August 2014 in Diabetologia.
A release from the university quotes study chairman Professor Tony Keech as saying, “The finding is good news for women. The study shows that fenofibrate reduced the risk of dying from cardiovascular disease, or having a stroke or other adverse cardiovascular event by 30 per cent in women and 13 per cent in men.”